Shanghai Henlius Biotech, Inc. (HKG:2696)

Market Cap	34.29B
Revenue (ttm)	6.35B
Net Income (ttm)	903.25M
Shares Out	543.49M
EPS (ttm)	1.66
PE Ratio	37.97
Forward PE	37.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	312,000
Average Volume	630,867
Open	63.10
Previous Close	63.10
Day's Range	60.10 - 63.10
52-Week Range	15.20 - 92.00
Beta	0.59
RSI	46.73
Earnings Date	Nov 14, 2025

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,515
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2696

Financial Performance

In 2024, Shanghai Henlius Biotech's revenue was 5.72 billion, an increase of 6.11% compared to the previous year's 5.39 billion. Earnings were 820.47 million, an increase of 50.26%.

Financial numbers in CNY